Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: A 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape)

Diabetes, Obesity and Metabolism

Volumn 17, Issue 12, 2015, Pages 1133-1141

  Vora, Jiten ^a   Cohen, N ^b   Evans, M ^c   Hockey, A ^d   Speight, J ^e,f,g   Whately Smith, C ^h  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c LLANDOUGH HOSPITAL   (United Kingdom)

^d Sanofi   (United Kingdom)

^e AHP Research   (United Kingdom)

^f THE AUSTRALIAN CENTRE FOR BEHAVIOURAL RESEARCH IN DIABETES   (Australia)

^g DEAKIN UNIVERSITY   (Australia)

^h Whately Smith Ltd   (United Kingdom)

Author keywords

Clinical trial; Insulin therapy; Phase IV; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; INSULIN GLULISINE; ANTIDIABETIC AGENT; BIPHASIC INSULIN; DRUG COMBINATION; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN; INSULIN ASPART, INSULIN ASPART PROTAMINE DRUG COMBINATION 30:70; ISOPHANE INSULIN;

ADULT; ARTICLE; AUDIT OF DIABETES DEPENDENT QUALITY OF LIFE; CONTROLLED STUDY; COUGHING; DIABETES TREATMENT SATISFACTION QUESTIONNAIRE; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FIVE DIMENSION EUROPEAN QUALITY OF LIFE QUESTIONNAIRE; GLYCEMIC CONTROL; HEADACHE; HEALTH STATUS; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT SATISFACTION QUESTIONNAIRE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; MULTICENTER STUDY; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OROPHARYNX PAIN; PARALLEL DESIGN; PATIENT SATISFACTION; PHASE 4 CLINICAL TRIAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; VOMITING; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; AUSTRALIA; BLOOD; BLOOD GLUCOSE MONITORING; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG COMBINATION; GREAT BRITAIN; HYPERGLYCEMIA; INCIDENCE; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; PATIENT DROPOUT;

AGED; AUSTRALIA; BIPHASIC INSULINS; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN, ISOPHANE; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PATIENT DROPOUTS; QUALITY OF LIFE;

EID: 84945309907     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12528     Document Type: Article

References (31)

1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 1999; 281: 2005-2012.
2. Holman R, Paul S, Bethel M, Matthews D, Neil H. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
3. Riddle M, Rosenstock J, Gerich J, Investigators IGS. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
4. Inzucchi S, Bergenstal R, Buse J etal. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
5. Ilag L, Kerr L, Malone J, Tan M. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 2007; 29: 1254-1270.
6. Liebl A, Prusty V, Valensi P etal. Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings. Drugs 2012; 72: 1495-1520.
7. Garber A. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006; 66: 31-49.
8. Raskin PR, Hollander PA, Lewin A et al. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med 2007; 18: 56-62.
9. Holman RR, Thorne KI, Farmer AJ etal. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-1730.
10. Holman RR, Farmer AJ, Davies MJ etal. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-1747.
11. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In: Bradley C, ed. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Chur, Switzerland: Harwood Academic Publishers, 1994; 111-132.
12. Bradley C. Diabetes Treatment Satisfaction Questionnaire: change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care 1999; 22: 530-532.
13. Anderson RT, Skovlund SE, Marrero D. Development and validation of the insulin treatment satisfaction questionnaire. Clin Ther 2004; 26: 565-578.
14. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res 1999; 8: 79-91.
15. Bradley C, Speight J. Patient perceptions of diabetes and diabetes therapy: assessing quality of life. Diabetes Metab Res Rev 2002; 18(Suppl. 3): S64-69.
16. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
17. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53-72.
18. Dolan P, Gudex C, Kind P etal. The time trade-off method: results from a general population study. Health Econ 1996; 5: 141-154.
19. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-1108.
20. European Medicines Agency. Committee for proprietary medicinal products. Note for guidance on statistical principles for clinical trials. CPMP/ICH/363/96 [Internet], 1998. Available from URL: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002928.pdf. Accessed 12 May 2014.
21. Food and Drug Administration. Guidance for Industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. [Internet], 2008. Available from URL: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm071624.pdf. Accessed 12 May 2014.
22. Speight J, Reaney MD, Barnard KD. Not all roads lead to Rome-a review of quality of life measurement in adults with diabetes. Diabet Med 2009; 26: 315-327.
23. Janssen MF, Lubetkin EI, Sekhobo JP, Pickard AS. The use of the EQ-5D preference-based health status measure in adults with type 2 diabetes mellitus. Diabet Med 2011; 28: 395-413.
24. Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. Diabetes Obes Metab 2011; 13: 1020-1027.
25. Riddle MC, Forst T, Aronson R etal. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 2013; 36: 2497-2503.
26. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M etal. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442-451.
27. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-259.
28. Fulcher GR, Christiansen JS, Bantwal G etal. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care 2014; 37: 2084-2090.
29. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care 2011; 34: 510-517.
30. Riddle MC, Rosenstock J, Vlajnic A, Gao L. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes Metab 2014; 16: 396-402.
31. Vora J, Cohen N, Evans M, Hockey A, Speight J, Whately-Smith C. Glycemic control and treatment satisfaction in type 2 diabetes: basal plus compared with biphasic insulin in the LANSCAPE trial [abstract]. Diabetes 2013; 62(suppl 1): 47-LB.